Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2018

View Archived Issues

Xencor opens enrollment in phase I study of XmAb-20717 for advanced solid tumors

FDA grants fast track designation for fimepinostat in relapsed or refractory DLBCL

Impel NeuroPharma initiates phase IIa trial of INP-103 in Parkinson's disease OFF episodes

Astellas submits application for marketing approval of peficitinib in Japan

Phase II study of MGL-3196 in NASH achieves liver biopsy endpoints at 36 weeks

Cortexyme announces USD 76 million financing and provides update on COR-388 clinical progress

Doptelet becomes available in the U.S. for the treatment of thrombocytopenia

Signs of clinical efficacy seen with HPV-specific T-cell therapy

Nektar Therapeutics submits NDA to the FDA for NKTR-181

Researchers identify GNMT as potential therapeutic target in UC and RCC

Astellas and FibroGen announce topline data from Japanese phase III study of roxadustat

Mithra announces further positive phase IIb efficacy and safety results for Donesta

Amgen and M.D. Anderson enter two multiyear collaboration agreements

Shionogi and Hsiri collaborate to discover and develop new treatments for mycobacterial diseases

Transfusion reductions seen with stem cell gene therapy for beta-thalassemia

Merck & Co. patents alpha7 receptor PAMs

Roche divulges gamma-secretase inhibitors

Bayer identifies new TANK1/2 inhibitors

Cancer Research Technology discloses CDC7 inhibitors

Bristol-Myers Squibb presents integrin alpha-V antagonists

Titan Pharmaceuticals and Braeburn terminate license agreement for Probuphine

Researchers identify ER-beta as a promoter of RCC progression

CapZ beta may be a biomarker of male infertility

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...